HA
ARKG icon

Harfst & Associates’s ARK Genomic Revolution ETF ARKG Stock Holding History

Harfst & Associates’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,229
Closed -$206K – 128
2021
Q2 		$206K Sell
2,229
-593
-21% -$50.4K 0.06% 127
2021
Q1 		$250K Buy
+2,822
New +$280K 0.08% 132

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Harfst & Associates's ARKG Position: Q3 2021 in Review

Harfst & Associates sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2021, closing a stake of 2,229 shares — an estimated $206K sold.

Harfst & Associates first reported a position in ARKG in Q1 2021 and held it in 2 quarters. The position peaked at $250K in Q1 2021. 468 funds tracked by Wall St. Rank hold ARKG as of Q3 2021.

  • Harfst & Associates reported no remaining ARK Genomic Revolution ETF position as of Q3 2021 after selling out during the quarter.
  • Harfst & Associates sold 2,229 ARK Genomic Revolution ETF shares in Q3 2021, an estimated $206K.
  • Harfst & Associates first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 2 quarters.
  • Harfst & Associates's ARK Genomic Revolution ETF position peaked at $250K in Q1 2021.
  • 468 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2021.

Based on Harfst & Associates's 13F filing for Q3 2021, filed 28 Oct 2021.